Terms: = Prostate cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
36 results:
1. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
2. Microarray-based identification of differentially expressed genes associated with andrographolide derivatives-induced resistance in colon and prostate cancer cell lines.
Quah SY; Wong CC; Wong HC; Ho KL; Abdul Manan N; Deb PK; Sagineedu SR; Stanslas J
Toxicol Appl Pharmacol; 2021 Aug; 425():115605. PubMed ID: 34087331
[TBL] [Abstract] [Full Text] [Related]
3. Effects of fgfr4 G388R, V10I polymorphisms on the likelihood of cancer.
Peng T; Sun Y; Lv Z; Zhang Z; Su Q; Wu H; Zhang W; Yuan W; Zuo L; Shi L; Zhang LF; Zhou X; Mi Y
Sci Rep; 2021 Jan; 11(1):1373. PubMed ID: 33446698
[TBL] [Abstract] [Full Text] [Related]
4. An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.
Moazeni-Roodi A; Sarabandi S; Karami S; Hashemi M; Ghavami S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33017009
[TBL] [Abstract] [Full Text] [Related]
5. Baseline quality of life predicts overall survival in patients with mCRPC treated with
Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
[TBL] [Abstract] [Full Text] [Related]
6. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract] [Full Text] [Related]
7. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced prostate cancer? A Meta-analysis.
Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
[TBL] [Abstract] [Full Text] [Related]
8. STEAP2 Knockdown Reduces the Invasive Potential of prostate cancer Cells.
Burnell SEA; Spencer-Harty S; Howarth S; Bodger O; Kynaston H; Morgan C; Doak SH
Sci Rep; 2018 Apr; 8(1):6252. PubMed ID: 29674723
[TBL] [Abstract] [Full Text] [Related]
9. Functional fgfr4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Xiong SW; Ma J; Feng F; Fu W; Shu SR; Ma T; Wu C; Liu GC; Zhu J
Oncotarget; 2017 Apr; 8(15):25300-25309. PubMed ID: 28445975
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic significance of fibroblast growth factor receptor 4 polymorphisms on biochemical recurrence after radical prostatectomy in a Chinese population.
Chen L; Lei Z; Ma X; Huang Q; Zhang X; Zhang Y; Hao P; Yang M; Zhao X; Chen J; Liu G; Zheng T
Sci Rep; 2016 Sep; 6():33604. PubMed ID: 27640814
[TBL] [Abstract] [Full Text] [Related]
11. Systematic meta-analyses of gene-specific genetic association studies in prostate cancer.
Hao Q; Wei D; Zhang Y; Chen X; Yang F; Yang Z; Zhu X; Wang J
Oncotarget; 2016 Apr; 7(16):22271-84. PubMed ID: 26967244
[TBL] [Abstract] [Full Text] [Related]
12. Germline variant fgfr4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract] [Full Text] [Related]
13. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression.
Feng S; Shao L; Yu W; Gavine P; Ittmann M
Clin Cancer Res; 2012 Jul; 18(14):3880-8. PubMed ID: 22573348
[TBL] [Abstract] [Full Text] [Related]
14. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma.
Yang Y; Zhou Y; Lu M; An Y; Li R; Chen Y; Lu DR; Jin L; Zhou WP; Qian J; Wang HY
Mol Carcinog; 2012 Jul; 51(7):515-21. PubMed ID: 21656577
[TBL] [Abstract] [Full Text] [Related]
15. Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis.
Liwei L; Chunyu L; Jie L; Ruifa H
Urol Int; 2011; 87(2):159-64. PubMed ID: 21625079
[TBL] [Abstract] [Full Text] [Related]
16. FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.
Yu W; Feng S; Dakhova O; Creighton CJ; Cai Y; Wang J; Li R; Frolov A; Ayala G; Ittmann M
Clin Cancer Res; 2011 Jul; 17(13):4355-66. PubMed ID: 21622724
[TBL] [Abstract] [Full Text] [Related]
17. Meta and pooled analyses of fgfr4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract] [Full Text] [Related]
18. fgfr4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls.
Xu B; Tong N; Chen SQ; Hua LX; Wang ZJ; Zhang ZD; Chen M
BMC Cancer; 2011 Feb; 11():84. PubMed ID: 21349172
[TBL] [Abstract] [Full Text] [Related]
19. The receptor tyrosine kinase fgfr4 negatively regulates NF-kappaB signaling.
Drafahl KA; McAndrew CW; Meyer AN; Haas M; Donoghue DJ
PLoS One; 2010 Dec; 5(12):e14412. PubMed ID: 21203561
[TBL] [Abstract] [Full Text] [Related]
20. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract] [Full Text] [Related]
[Next]
